<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33993490</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>129</EndPage><MedlinePgn>118-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.14907</ELocationID><Abstract><AbstractText Label="BACKGROUND">COVID-19 can present with lymphopenia and extraordinary complex multiorgan pathologies that can trigger long-term sequela.</AbstractText><AbstractText Label="AIMS">Given that inflammasome products, like caspase-1, play a role in the pathophysiology of a number of co-morbid conditions, we investigated caspases across the spectrum of COVID-19 disease.</AbstractText><AbstractText Label="MATERIALS &amp; METHODS">We assessed transcriptional states of multiple caspases and using flow cytometry, the expression of active caspase-1 in blood cells from COVID-19 patients in acute and convalescent stages of disease. Non-COVID-19 subject presenting with various comorbid conditions served as controls.</AbstractText><AbstractText Label="RESULTS">Single-cell RNA-seq data of immune cells from COVID-19 patients showed a distinct caspase expression pattern in T cells, neutrophils, dendritic cells, and eosinophils compared with controls. Caspase-1 was upregulated in CD4+&#xa0;T-cells from hospitalized COVID-19 patients compared with unexposed controls. Post-COVID-19 patients with lingering symptoms (long-haulers) also showed upregulated caspase-1activity in CD4+&#xa0;T-cells that&#xa0;ex vivo&#xa0;was attenuated with a select pan-caspase inhibitor. We observed elevated caspase-3/7levels in red blood cells from COVID-19 patients compared with controls that was reduced following caspase inhibition.</AbstractText><AbstractText Label="DISCUSSION">Our preliminary results suggest an exuberant caspase response in COVID-19 that may facilitate immune-related pathological processes leading to severe outcomes. Further clinical correlations of caspase expression in different stages of COVID-19 will be needed.</AbstractText><AbstractText Label="CONCLUSION">Pan-caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2021 European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plassmeyer</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alpan</LastName><ForeName>Oral</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-7467-8541</Identifier><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corley</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premeaux</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-2103-3421</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lillard</LastName><ForeName>Kimberleigh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coatney</LastName><ForeName>Paige</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaziri</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalsky</LastName><ForeName>Suzan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Alina P S</ForeName><Initials>APS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukhari</LastName><ForeName>Zaheer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>S.U.N.Y. Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evering</LastName><ForeName>Teresa H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naughton</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Histogen, Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latterich</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Histogen, Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudd</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spada</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Histogen, Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rindone</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Histogen, Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loizou</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Histogen, Inc, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrik S&#xf8;nder</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Amerimmune, Fairfax, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndhlovu</LastName><ForeName>Lishomwa C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Raavi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>S.U.N.Y. Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 HL140271</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505520">CASP7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053179">Caspase 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053179" MajorTopicYN="N">Caspase 7</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="Y">Caspase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">T-helper cell</Keyword><Keyword MajorTopicYN="N">caspase</Keyword><Keyword MajorTopicYN="N">emricasan</Keyword><Keyword MajorTopicYN="N">red blood cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>16</Day><Hour>21</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33993490</ArticleId><ArticleId IdType="pmc">PMC8222863</ArticleId><ArticleId IdType="doi">10.1111/all.14907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fauci AS, Lane HC, Redfield RR. Covid&#x2013;19 &#x2010; Navigating the uncharted. N Engl J Med. 2020;382(13):1268&#x2010;1269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121221</ArticleId><ArticleId IdType="pubmed">32109011</ArticleId></ArticleIdList></Reference><Reference><Citation>Paules CI, Marston HD, Fauci AS. Coronavirus infections&#x2010;more than just the common cold. JAMA. 2020;323(8):707&#x2010;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">31971553</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow A, Landolf KM, Barlow B, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020;40(5):416&#x2010;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262196</ArticleId><ArticleId IdType="pubmed">32259313</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC , Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid&#x2010;19 &#x2010; preliminary report. N Engl J Med. 2020;384(8):693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Han M, Li T, et al. Effective treatment of severe COVID&#x2010;19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970&#x2010;10975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID&#x2010;19: a randomized clinical trial. JAMA. 2020;324(11):1048&#x2010;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>White KM, Rosales R, Yildiz S, et al. Plitidepsin has potent preclinical efficacy against SARS&#x2010;CoV&#x2010;2 by targeting the host protein eEF1A. Science. 2021;371(6532):926&#x2010;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963220</ArticleId><ArticleId IdType="pubmed">33495306</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijotas&#x2010;Reig J, Esteve&#x2010;Valverde E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID&#x2010;19. Beyond the anti&#x2010;viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252146</ArticleId><ArticleId IdType="pubmed">32376394</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS&#x2010;CoV&#x2010;2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014&#x2010;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Soy M, Keser G, Atagunduz P, Tabak F, Atagunduz I, Kayhan S. Cytokine storm in COVID&#x2010;19: pathogenesis and overview of anti&#x2010;inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085&#x2010;2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260446</ArticleId><ArticleId IdType="pubmed">32474885</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID&#x2010;19 update: Covid&#x2010;19&#x2010;associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54&#x2010;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasoksuz M, Kilic S, Sarac F. Turk J Med Sci. 2020;50(SI&#x2010;1):549&#x2010;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195990</ArticleId><ArticleId IdType="pubmed">32293832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS&#x2010;CoV&#x2010;2 mimicking Kawasaki disease (Kawa&#x2010;COVID&#x2010;19): a multicentre cohort. Ann Rheum Dis. 2020;79(8):999&#x2010;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299653</ArticleId><ArticleId IdType="pubmed">32527868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID&#x2010;19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506&#x2010;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094929</ArticleId><ArticleId IdType="pubmed">32284616</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, et al. COVID&#x2010;19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2010;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;ant JL, Gu&#xe9;ant&#x2010;Rodriguez RM, Fromonot J, et al. Elastase and exacerbation of neutrophil innate immunity are involved in multi&#x2010;visceral manifestations of COVID&#x2010;19. Allergy. 2021;76(6):1846&#x2010;1858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014109</ArticleId><ArticleId IdType="pubmed">33484168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo&#x2010;Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID&#x2010;19. Nature. 2021;591(7848):92&#x2010;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS&#x2010;CoV&#x2010;2 infection and are associated with COVID&#x2010;19 severity in patients. J Exp Med. 2021;218(3):e20201707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer A, Khan K, Plassmeyer M, et al. Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID&#x2010;19. J Hepatol. 2020;73(5):1258&#x2010;1262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336919</ArticleId><ArticleId IdType="pubmed">32645361</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid M, Busman&#x2010;Sahay K, Vidal SJ, et al. Vascular disease and thrombosis in SARS&#x2010;CoV&#x2010;2&#x2010;infected rhesus macaques. Cell. 2020;183(5):1354&#x2010;1366.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546181</ArticleId><ArticleId IdType="pubmed">33065030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YL, Zhai JH, Chai YF. Recent advances in the molecular mechanisms underlying pyroptosis in sepsis. Mediators Inflamm. 2018;2018:5823823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863298</ArticleId><ArticleId IdType="pubmed">29706799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia C, Chen H, Zhang J, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311&#x2010;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">30572256</ArticleId></ArticleIdList></Reference><Reference><Citation>Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277(1):61&#x2010;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5416822</ArticleId><ArticleId IdType="pubmed">28462526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27(9):673&#x2010;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565696</ArticleId><ArticleId IdType="pubmed">28619472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. Cell Res. 2018;28(1):9&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5752838</ArticleId><ArticleId IdType="pubmed">29076500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher TA. Apoptosis. Ann Allergy Asthma Immunol. 1997;78(3):245&#x2010;250; quiz 9&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087147</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti J, Blander JM. Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol. 2020;109(3):561&#x2010;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985609</ArticleId><ArticleId IdType="pubmed">32531835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID&#x2010;19? Cytokine and anti&#x2010;cytokine interventions. Autoimmun Rev. 2020;19(7):102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Samkari H, Karp Leaf RS, Dzik WH, et al. COVID&#x2010;19 and coagulation: bleeding and thrombotic manifestations of SARS&#x2010;CoV&#x2010;2 infection. Blood. 2020;136(4):489&#x2010;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378457</ArticleId><ArticleId IdType="pubmed">32492712</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C, Maphumulo SC, Grobbelaar LM, et al. Covid&#x2010;19: the rollercoaster of fibrin(Ogen), D&#x2010;Dimer, von willebrand factor, P&#x2010;selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020;21(14):5168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, et al. A single&#x2010;cell atlas of the peripheral immune response in patients with severe COVID&#x2010;19. Nat Med. 2020;26(7):1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco&#x2010;Melo D, Nilsson&#x2010;Payant BE, Liu WC, et al. Imbalanced host response to SARS&#x2010;CoV&#x2010;2 drives development of COVID&#x2010;19. Cell. 2020;181(5):1036&#x2010;1045 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C&#x2010;P&#x2010;ACSG. Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324(6):603&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Arora U, Kumar A, Wig N. The, "post&#x2010;COVID" syndrome: how deep is the damage? J Med Virol. 2020;93(2):673&#x2010;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461449</ArticleId><ArticleId IdType="pubmed">32852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Linton SD, Aja T, Armstrong RA, et al. First&#x2010;in&#x2010;class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem. 2005;48(22):6779&#x2010;6782.</Citation><ArticleIdList><ArticleId IdType="pubmed">16250635</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack JH, Beaumont K, Larsen PD, et al. IL&#x2010;converting enzyme/caspase&#x2010;1 inhibitor VX&#x2010;765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005;175(4):2630&#x2010;2634.</Citation><ArticleIdList><ArticleId IdType="pubmed">16081838</ArticleId></ArticleIdList></Reference><Reference><Citation>Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS&#x2010;CoV&#x2010;2 infection. JAMA Netw Open. 2020;3(9):e2022058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7512057</ArticleId><ArticleId IdType="pubmed">32965501</ArticleId></ArticleIdList></Reference><Reference><Citation>Maellaro E, Leoncini S, Moretti D, et al. Erythrocyte caspase&#x2010;3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol. 2013;50(4):489&#x2010;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">21437568</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Stefanoni D, Dzieciatkowska M, et al. Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID&#x2010;19 patients. J Proteome Res. 2020. 10.1101/2020.06.29.20142703</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.29.20142703</ArticleId><ArticleId IdType="pmc">PMC7640979</ArticleId><ArticleId IdType="pubmed">33103907</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID&#x2010;19 in previously healthy children and adolescents in New York City. JAMA. 2020;324(3):294&#x2010;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281352</ArticleId><ArticleId IdType="pubmed">32511676</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Tang K, Levin M, et al. COVID&#x2010;19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276&#x2010;e288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431129</ArticleId><ArticleId IdType="pubmed">32818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh&#x2010;Grewal D, Lucas R, McCarthy K, et al. Update on the COVID&#x2010;19&#x2010;associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome&#x2010;temporally associated with SARS&#x2010;CoV&#x2010;2. J Paediatr Child Health. 2020;56(8):1173&#x2010;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436879</ArticleId><ArticleId IdType="pubmed">32735721</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID&#x2010;19 in the New York city area. JAMA. 2020;323(20):2052&#x2010;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and pyroptosis as therapeutic targets for COVID&#x2010;19. J Immunol. 2020;205(2):307&#x2010;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343621</ArticleId><ArticleId IdType="pubmed">32493814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014;1319:82&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074217</ArticleId><ArticleId IdType="pubmed">24840700</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL&#x2010;1 to IL&#x2010;38), interferons, transforming growth factor beta, and TNF&#x2010;alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984&#x2010;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">27577879</ArticleId></ArticleIdList></Reference><Reference><Citation>Arend WP, Palmer G, Gabay C. IL&#x2010;1, IL&#x2010;18, and IL&#x2010;33 families of cytokines. Immunol Rev. 2008;223:20&#x2010;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18613828</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012&#x2010;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123939</ArticleId><ArticleId IdType="pubmed">27669650</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397&#x2010;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807999</ArticleId><ArticleId IdType="pubmed">23702978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID&#x2010;19 patients. Cell Host Microbe. 2020;27(6):883&#x2010;390 e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Labzin LI, Lauterbach MA, Latz E. Interferons and inflammasomes: cooperation and counterregulation in disease. J Allergy Clin Immunol. 2016;138(1):37&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">27373324</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991&#x2010;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">8011301</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301&#x2010;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11951032</ArticleId></ArticleIdList></Reference><Reference><Citation>Carelli&#x2010;Alinovi C, Pirolli D, Giardina B, Misiti F. Protein kinase C mediates caspase 3 activation: a role for erythrocyte morphology changes. Clin Hemorheol Microcirc. 2015;59(4):345&#x2010;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">24840342</ArticleId></ArticleIdList></Reference><Reference><Citation>Firat U, Kaya S, Cim A, et al. Increased caspase&#x2010;3 immunoreactivity of erythrocytes in STZ diabetic rats. Exp Diabetes Res. 2012;2012:316384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350965</ArticleId><ArticleId IdType="pubmed">22611373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinalducci S, Ferru E, Blasi B, Turrini F, Zolla L. Oxidative stress and caspase&#x2010;mediated fragmentation of cytoplasmic domain of erythrocyte band 3 during blood storage. Blood Transfus. 2012;10(Suppl 2):s55&#x2010;s62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418627</ArticleId><ArticleId IdType="pubmed">22890269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zini G, Bellesi S, Ramundo F, d'Onofrio G. Morphological anomalies of circulating blood cells in COVID&#x2010;19. Am J Hematol. 2020;95(7):870&#x2010;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262044</ArticleId><ArticleId IdType="pubmed">32279346</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang X, Qiao J, et al. A controllable inflammatory response and temporary abnormal coagulation in moderate disease of COVID&#x2010;19 in Wuhan, China. J Clin Med Res. 2020;12(9):590&#x2010;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430917</ArticleId><ArticleId IdType="pubmed">32849947</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomar B, Anders HJ, Desai J, Mulay SR. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID&#x2010;19. Cells. 2020;9(6):1383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7348784</ArticleId><ArticleId IdType="pubmed">32498376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiewiora M, Piecuch J, Sedek L, Mazur B, Sosada K. The effects of obesity on CD47 expression in erythrocytes. Cytometry B Clin Cytom. 2017;92(6):485&#x2010;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">25914268</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini JJ, Gattinoni L. Management of COVID&#x2010;19 respiratory distress. JAMA. 2020;323(22):2329&#x2010;2330.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329799</ArticleId></ArticleIdList></Reference><Reference><Citation>Neupane K, Ahmed Z, Pervez H, Ashraf R, Majeed A. Potential treatment options for COVID&#x2010;19: a comprehensive review of global pharmacological development efforts. Cureus. 2020;12(6):e8845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386097</ArticleId><ArticleId IdType="pubmed">32754388</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahzad K, Bock F, Al&#x2010;Dabet MM, et al. Caspase&#x2010;1, but not Caspase&#x2010;3, promotes diabetic nephropathy. J Am Soc Nephrol. 2016;27(8):2270&#x2010;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978051</ArticleId><ArticleId IdType="pubmed">26832955</ArticleId></ArticleIdList></Reference><Reference><Citation>Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA. 2002;99(9):6252&#x2010;6256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122935</ArticleId><ArticleId IdType="pubmed">11972044</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenette CT, Morelli G, Shiffman ML, et al. Emricasan improves liver function in patients with cirrhosis and high model for end&#x2010;stage liver disease scores compared with placebo. Clin Gastroenterol Hepatol. 2019;17(4):774&#x2010;783 e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29913280</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreyro FJ, Holod S, Finocchietto PV, et al. The pan&#x2010;caspase inhibitor Emricasan (IDN&#x2010;6556) decreases liver injury and fibrosis in a murine model of non&#x2010;alcoholic steatohepatitis. Liver Int. 2015;35(3):953&#x2010;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750664</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo&#x2010;controlled trial of emricasan in patients with NASH and F1&#x2013;F3 fibrosis. J Hepatol. 2020;72(5):816&#x2010;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">31887369</ArticleId></ArticleIdList></Reference><Reference><Citation>Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T&#x2010;cell depletion in HIV&#x2010;1 infection. Nature. 2014;505(7484):509&#x2010;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047036</ArticleId><ArticleId IdType="pubmed">24356306</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID&#x2010;19: a prospective autopsy cohort study. Lancet Microbe. 2020;1(7):e290&#x2010;e299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Zhang J, Cha Y, et al. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease&#x2010;2019 (COVID&#x2010;19). J Transl Med. 2020;18(1):257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315012</ArticleId><ArticleId IdType="pubmed">32586380</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JD, Uhrich RL, Kraemer GC, Love JE, Kraemer BC. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS&#x2010;CoV&#x2010;2 main 1 protease; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850479</ArticleId><ArticleId IdType="pubmed">33524017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A, Jackson R, Harman CC, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell. 2014;159(7):1563&#x2010;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272443</ArticleId><ArticleId IdType="pubmed">25525875</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Daley&#x2010;Bauer LP, Roback L, et al. Caspase&#x2010;8 restricts antiviral CD8 T cell hyperaccumulation. Proc Natl Acad Sci USA. 2019;116(30):15170&#x2010;15177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660791</ArticleId><ArticleId IdType="pubmed">31285326</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Tsao G, Bosch J, Kayali Z, et al. Randomized placebo&#x2010;controlled trial of emricasan for non&#x2010;alcoholic steatohepatitis&#x2010;related cirrhosis with severe portal hypertension. J Hepatol. 2020;72(5):885&#x2010;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">31870950</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaqinuddin A, Kashir J. Novel therapeutic targets for SARS&#x2010;CoV&#x2010;2&#x2010;induced acute lung injury: targeting a potential IL&#x2010;1beta/neutrophil extracellular traps feedback loop. Med Hypotheses. 2020;143:109906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834360</ArticleId><ArticleId IdType="pubmed">32505910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani RD, Dabas N, Goldberger JJ. COVID&#x2010;19 cardiac injury: Implications for long&#x2010;term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984&#x2010;1990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319645</ArticleId><ArticleId IdType="pubmed">32599178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>